• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种与1型纤溶酶原激活物抑制剂缺乏相关的终身性出血性疾病。

A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.

作者信息

Diéval J, Nguyen G, Gross S, Delobel J, Kruithof E K

机构信息

Laboratory of Hematology, University Hospital, Amiens, France.

出版信息

Blood. 1991 Feb 1;77(3):528-32.

PMID:1899347
Abstract

A 36-year-old patient was investigated for a lifelong history of epistaxis and delayed bleeding after minor surgeries. Deficiencies or abnormalities of the coagulation system, of platelet function, or of factor XIII and alpha-2-antiplasmin were excluded. Consistently, however, over a period of 7 years, a high basal euglobulin fibrinolytic activity was observed that was characterized by a high tissue-type plasminogen activator (t-PA) activity, normal t-PA antigen, and undetectable plasminogen activator inhibitor type-1 (PAI-1) antigen and activity. The high specific activity of t-PA (640,000 IU/mg) and the minimal amounts of t-PA/PAI-1 complexes detected by fibrin zymography suggest that in this patient all t-PA was active. This is in striking contrast to normal plasma, where the majority of t-PA is complexed to PAI-1. Thus, in this patient, a severe deficiency of PAI-1 is associated with a delayed type bleeding tendency. Our observation underscores the importance of plasma PAI-1 for the stabilization of the hemostatic plug.

摘要

一名36岁患者因终生鼻出血及小手术后出血延迟而接受检查。排除了凝血系统、血小板功能、因子XIII和α-2-抗纤溶酶的缺乏或异常。然而,在7年的时间里,持续观察到高基础优球蛋白纤维蛋白溶解活性,其特征为高组织型纤溶酶原激活物(t-PA)活性、正常t-PA抗原,且未检测到纤溶酶原激活物抑制剂-1(PAI-1)抗原及活性。t-PA的高比活性(640,000 IU/mg)以及纤维蛋白酶谱检测到的极少量t-PA/PAI-1复合物表明,该患者体内所有t-PA均具有活性。这与正常血浆形成鲜明对比,在正常血浆中,大多数t-PA与PAI-1结合。因此,在该患者中,PAI-1严重缺乏与延迟性出血倾向相关。我们的观察结果强调了血浆PAI-1对止血栓稳定的重要性。

相似文献

1
A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.一种与1型纤溶酶原激活物抑制剂缺乏相关的终身性出血性疾病。
Blood. 1991 Feb 1;77(3):528-32.
2
Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.经尿道前列腺切除术患者血液纤溶与术中或术后即刻失血之间缺乏相关性。
Br J Urol. 1997 Jul;80(1):105-10. doi: 10.1046/j.1464-410x.1997.00251.x.
3
Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.由于1型纤溶酶原激活物抑制剂功能活性降低导致的出血素质
J Clin Invest. 1989 May;83(5):1747-52. doi: 10.1172/JCI114076.
4
Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor.组织型纤溶酶原激活物与纤溶酶原激活物抑制剂-1、α2-巨球蛋白及C1抑制物的复合物形成:电击或复杂分娩后去纤维蛋白和纤溶状态患者的研究
Blood. 1990 Feb 1;75(3):671-6.
5
[Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome].
Rinsho Byori. 1991 Jul;39(7):720-6.
6
The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis.静脉淤滞后纤溶酶原激活剂(组织型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂)及纤溶酶原激活剂抑制剂-1的释放
Blood Coagul Fibrinolysis. 1992 Feb;3(1):33-8. doi: 10.1097/00001721-199202000-00006.
7
The activation of plasminogen by T-PA-PAI-1 complex in the absence of fibrin.在无纤维蛋白的情况下,组织型纤溶酶原激活物-纤溶酶原激活物抑制剂-1复合物对纤溶酶原的激活作用。
Thromb Res. 1991 Jul 1;63(1):169-77. doi: 10.1016/0049-3848(91)90279-6.
8
Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.肝脏疾病中的组织型纤溶酶原激活剂、纤溶酶原激活剂抑制剂及激活剂-抑制剂复合物
J Clin Pathol. 1994 Mar;47(3):214-7. doi: 10.1136/jcp.47.3.214.
9
Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.血浆纤溶酶原激活物抑制剂1缺乏会导致高纤溶出血。
Blood. 1993 May 1;81(9):2357-62.
10
Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.与纤维蛋白结合的1型纤溶酶原激活物抑制剂(PAI-1)与组织型纤溶酶原激活物(t-PA)或尿激酶型纤溶酶原激活物(u-PA)之间的相互作用。t-PA的指状结构域和kringle-2结构域介导t-PA/PAI-1复合物与纤维蛋白的结合。
J Clin Invest. 1989 Aug;84(2):647-55. doi: 10.1172/JCI114211.

引用本文的文献

1
Identification of a Novel Mutation in the SERPINE1 Gene Causing Clinical Hyperfibrinolysis in English Springer Spaniel Dogs.在英国激飞猎犬中鉴定出导致临床高纤溶血症的SERPINE1基因新突变。
J Vet Intern Med. 2025 Jul-Aug;39(4):e70150. doi: 10.1111/jvim.70150.
2
The role of the platelet pool of Plasminogen Activator Inhibitor-1 in well-controlled type 2 diabetes patients.纤溶酶原激活物抑制剂-1 血小板池在血糖控制良好的 2 型糖尿病患者中的作用。
PLoS One. 2022 Aug 31;17(8):e0267833. doi: 10.1371/journal.pone.0267833. eCollection 2022.
3
Porphyromonas gingivalis Gingipains-Mediated Degradation of Plasminogen Activator Inhibitor-1 Leads to Delayed Wound Healing Responses in Human Endothelial Cells.
牙龈卟啉单胞菌牙龈蛋白酶介导的纤溶酶原激活物抑制剂-1 降解导致人血管内皮细胞伤口愈合反应延迟。
J Innate Immun. 2022;14(4):306-319. doi: 10.1159/000519737. Epub 2021 Nov 25.
4
Deep mutational scanning of the plasminogen activator inhibitor-1 functional landscape.深突变扫描纤溶酶原激活物抑制剂-1 的功能图谱。
Sci Rep. 2021 Sep 22;11(1):18827. doi: 10.1038/s41598-021-97871-7.
5
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.心血管疾病中靶向纤溶酶原激活物抑制剂-1:纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
6
PAI-1, the Plasminogen System, and Skeletal Muscle.纤溶酶原激活物抑制物-1、纤溶酶原系统与骨骼肌
Int J Mol Sci. 2020 Sep 25;21(19):7066. doi: 10.3390/ijms21197066.
7
Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty.纤溶酶原激活物抑制剂-1:全髋关节置换术后深静脉血栓形成的一个危险因素。
J Orthop Surg Res. 2018 Jan 10;13(1):8. doi: 10.1186/s13018-018-0716-2.
8
Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.纤溶酶原激活物抑制剂-1的化学拮抗剂:作用机制及在血管疾病中的治疗潜力
J Mol Genet Med. 2014 Oct;8(3). doi: 10.4172/1747-0862.1000125.
9
Functional stability of plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1的功能稳定性
ScientificWorldJournal. 2014;2014:858293. doi: 10.1155/2014/858293. Epub 2014 Oct 15.
10
Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.纤溶酶原激活物抑制剂-1的低分子量拮抗剂:在心血管疾病中的治疗潜力
Mol Med Ther. 2012 Aug 5;1(1):101. doi: 10.4172/2324-8769.1000102.